{"TopicDetails": {"type": 0, "ccm2Id": 46939063, "cftId": 0, "identifier": "HORIZON-MISS-2024-CANCER-01-04", "title": "Support a pragmatic clinical trial programme by cancer charities", "publicationDateLong": 1713398400000, "callIdentifier": "HORIZON-MISS-2024-CANCER-01", "callTitle": "Research and Innovation actions supporting the implementation of the Mission on Cancer", "callccm2Id": 46939155, "allowPartnerSearch": true, "frameworkProgramme": {"id": 43108390, "abbreviation": "HORIZON", "description": "Horizon Europe Framework Programme (HORIZON)"}, "programmeDivision": [{"id": 43108557, "abbreviation": "HORIZON.2.1", "description": "Health"}, {"id": 43108541, "abbreviation": "HORIZON.2", "description": "Global Challenges and European Industrial Competitiveness"}], "missionDetails": "<p>The goal of the Mission on Cancer is to improve the lives of more than 3 million people by 2030, through prevention, cure and for those affected by cancer including their families, to live longer and better. The objectives include: Understand; Prevent what is preventable; Optimise diagnostics and treatment; Support quality of life; Ensure equitable access in all aforementioned areas. The Mission on Cancer will address all cancers including poorly-understood cancers[[<sup> </sup>Includes refractory cancers or cancer subtypes, at any stage of the disease in any age group and part of society with a 5-year overall survival that is less than 50% from time of diagnosis.]] in men and women, cancers in children, adolescents and young adults as well as in the elderly, cancers in socio-economically vulnerable populations, living in either cities, rural or remote areas, across all Member States and Associated countries.</p><p>The Mission on Cancer is implemented using a health-in-all policies approach[[<sup> </sup>Health in All Policies is an approach to public policies across sectors that systematically takes into account the health implications of decisions, seeks synergies, and avoids harmful health impacts in order to improve population health and health equity. <a href=\"https://www.who.int/social_determinants/publications/health-policies-manual/key-messages-en.pdf\">https://www.who.int/social_determinants/publications/health-policies-manual/key-messages-en.pdf</a>]]; through infrastructure support; regional, social and citizen community development; through investments; support and commitments from public and private sources, including from Member States, Associated countries and industry; through cooperation with third countries; and through synergies with other existing EU programmes including EU4HEALTH, EURATOM, Digital Europe, Erasmus+, the EU Strategic Framework on Health and Safety at Work 2021-2027 and other initiatives related to cancer.</p><p>It also relates to the European Green Deal, including the Farm to Fork strategy[[<sup> </sup><a href=\"https://ec.europa.eu/food/farm2fork_en\">https://ec.europa.eu/food/farm2fork_en</a>]]. The mission proposes research and policy directions and objectives to identify effective strategies for the development and implementation of cancer prevention, including on environmental factors (e.g. exposure to workplace carcinogens, air pollution, unhealthy diet, nutrition and low physical activity).</p><p>Furthermore, it is also in line with the industrial[[<sup> </sup><a href=\"https://ec.europa.eu/info/strategy/priorities-2019-2024/europe-fit-digital-age/european-industrial-strategy_en\">https://ec.europa.eu/info/strategy/priorities-2019-2024/europe-fit-digital-age/european-industrial-strategy_en</a>]] and digitalisation strategy[[<sup> </sup><a href=\"https://ec.europa.eu/info/strategy/priorities-2019-2024/europe-fit-digital-age_en\">https://ec.europa.eu/info/strategy/priorities-2019-2024/europe-fit-digital-age_en</a>]]. The mission proposes a further upscaling and digitalisation of services, innovation in diagnostics and interventions, and establishing living labs, contributing to the positive impact of efforts by industry and SMEs on the health of citizens. Envisaged opportunities are in the fields of: cancer biomarkers; cloud computing and digital applications, smart apps/sensors. The mission also supports the integration of AI, machine learning and deep learning approaches to facilitate a better understanding of cancer, to improve prevention screening and early detection, diagnosis, clinical decision-making, administration of combinational therapies, and clinical management of patients living with and after cancer.</p><p>Calls for proposals under this mission should contribute to setting out a credible pathway for implementing the Mission on Cancer, thereby contributing to mission objectives.</p><p>Proposals for topics under this Mission should set out a credible pathway to improving Cancer control, and more specifically to all of the following impacts:</p><ul level=\"0\"><li>Improve understanding of the development of cancer in the context of the environment, work, and lifestyle in the broadest possible sense,</li><li>Enhance cross-policy cancer prevention strategies,</li><li>Optimise the diagnostics and treatment of cancer based on the principle of equitable access,</li><li>Improve the quality of life of cancer patients, survivors and their families through widely analysing all key factors and needs that are related to the quality of life,</li><li>Accelerate the digital transformation of research, innovation and health systems.</li> </ul><p>The implementation plan specifies the goal and four main objectives as well as implementation details of the Mission on Cancer[[<a href=\"https://ec.europa.eu/info/sites/default/files/research_and_innovation/funding/documents/cancer_implementation_plan_for_publication_final_v2.pdf\">https://ec.europa.eu/info/sites/default/files/research_and_innovation/funding/documents/cancer_implementation_plan_for_publication_final_v2.pdf</a>]].</p><p>In the calls described below, the Commission envisages several actions[[<sup> </sup>The listed areas for potential actions are tentative and non-binding.]]: On the Cancer Mission objective <em>Understanding</em>, the Commission plans to address tumour-host interactions to enhance prevention, treatment and care interventions in poorly-understood childhood as well as adult cancer patients. On the Cancer Mission objective <em>Prevention</em>, the Commission foresees an action on behaviour change. On the Cancer Mission objective <em>Diagnosis and treatment</em>, the Commission envisages an action on minimally invasive diagnostics, which will also improve the quality of life. On the Cancer Mission objective <em>Quality of life</em>, the Commission envisages to enhance the quality of life for survivors of childhood cancer by setting up oncology-centred living labs. The society will benefit from a reduced burden of cancer and solving healthcare barriers.</p>", "missionDescription": "Mission: Cancer (2023/24)", "topicMGAs": [], "tags": ["cancer", "clinical trials", "cancer patient", "co-morbidities"], "keywords": ["Health services, health care research", "Quality of health care", "Clinical trials", "Technology implementation", "Digital Agenda", "Gender in health sciences", "Diagnostic technology", "Co-morbidity", "Anticancer therapy", "Social sciences and humanities", "Artificial Intelligence & Decision support", "Public health", "Personalised medicine", "EOSC and FAIR data", "Artificial Intelligence", "Societal Engagement", "Diagnostics", "Personalised prevention"], "flags": ["DigitalAgenda", "SSH", "EoscAndFairData", "AI", "SocietalEngagement"], "sme": false, "actions": [{"status": {"id": 31094502, "abbreviation": "Open", "description": "Open"}, "types": [{"typeOfAction": "HORIZON-CSA HORIZON Coordination and Support Actions", "typeOfMGA": [{"id": 43027846, "abbreviation": "HORIZON-AG", "description": "HORIZON Action Grant Budget-Based"}]}], "plannedOpeningDate": "18 April 2024", "submissionProcedure": {"id": 31094504, "abbreviation": "single-stage", "description": "single-stage"}, "deadlineDates": ["18 September 2024"]}], "latestInfos": [], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3523464": [{"action": "HORIZON-MISS-2024-CANCER-01-04 - HORIZON-CSA HORIZON Coordination and Support Actions", "plannedOpeningDate": "18 April 2024", "deadlineModel": "single-stage", "deadlineDates": ["18 September 2024"], "budgetYearMap": {"2024": 2999999.9}, "expectedGrants": 1, "minContribution": 3000000, "maxContribution": 3000000, "budgetTopicActionMap": {}}], "3523468": [{"action": "HORIZON-MISS-2024-CANCER-01-05 - HORIZON-RIA HORIZON  Research and Innovation Actions", "plannedOpeningDate": "18 April 2024", "deadlineModel": "single-stage", "deadlineDates": ["18 September 2024"], "budgetYearMap": {"2024": 35999999.98}, "expectedGrants": 6, "minContribution": 4000000, "maxContribution": 6000000, "budgetTopicActionMap": {}}], "3523472": [{"action": "HORIZON-MISS-2024-CANCER-01-02 - HORIZON-CSA HORIZON Coordination and Support Actions", "plannedOpeningDate": "18 April 2024", "deadlineModel": "single-stage", "deadlineDates": ["18 September 2024"], "budgetYearMap": {"2024": 2999999.9}, "expectedGrants": 1, "minContribution": 3000000, "maxContribution": 3000000, "budgetTopicActionMap": {}}], "3523476": [{"action": "HORIZON-MISS-2024-CANCER-01-01 - HORIZON-RIA HORIZON  Research and Innovation Actions", "plannedOpeningDate": "18 April 2024", "deadlineModel": "single-stage", "deadlineDates": ["18 September 2024"], "budgetYearMap": {"2024": 30000000.0}, "expectedGrants": 1, "minContribution": 30000000, "maxContribution": 30000000, "budgetTopicActionMap": {}}], "3523480": [{"action": "HORIZON-MISS-2024-CANCER-01-03 - HORIZON-IA HORIZON Innovation Actions", "plannedOpeningDate": "18 April 2024", "deadlineModel": "single-stage", "deadlineDates": ["18 September 2024"], "budgetYearMap": {"2024": 34999999.95}, "expectedGrants": 3, "minContribution": 10000000, "maxContribution": 12000000, "budgetTopicActionMap": {}}], "3523484": [{"action": "HORIZON-MISS-2024-CANCER-01-06 - HORIZON-IA HORIZON Innovation Actions", "plannedOpeningDate": "18 April 2024", "deadlineModel": "single-stage", "deadlineDates": ["18 September 2024"], "budgetYearMap": {"2024": 11999999.96}, "expectedGrants": 1, "minContribution": 12000000, "maxContribution": 12000000, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2024"]}, "description": "<SPAN class=\"topicdescriptionkind\">ExpectedOutcome</SPAN>:<p>An important aim of Missions is bringing together various disciplines, sectors and actors, such as philanthropy. Hundreds of cancer charities and foundations across Europe support patient-centred research, including clinical trials.</p><p>Pragmatic clinical trials focus on choosing between care options. Pragmatic trials evaluate effectiveness, the effect of treatment in routine (real-world) clinical practice. Some examples include treatment versus active surveillance in patient management, a combination of treatment interventions, determination of optimal dose and dose schedules, de-escalation of treatment intervention, comparative effectiveness of different treatment interventions.</p><p>The successful proposal under this topic should aim to deliver results that are directed and tailored towards and contribute to all of the following expected outcomes:</p><ul level=\"0\"><li>Together, a network of registered cancer charities and foundations support multi-centre, transnational pragmatic clinical trials on cancers with a 5-year overall survival less than 50% from time of diagnosis or rare cancers using their own resources.</li><li>Cancer patients and their caregivers have access to more effective and patient-centred, treatment and care solutions.</li><li>Researchers, innovators, and professionals from different disciplines and sectors ensure accessibility and re-usability of relevant trial data, to support the UNCAN.eu<sup><a target=_self href=#fn1 id=r1>[1]</a></sup> research data platform, which is currently in preparation.</li><li>National healthcare providers, policymakers and authorities in European regions, Member States and Associated Countries have the evidence to implement affordable and accessible treatment and care solutions in their healthcare systems.</li> </ul>\n<SPAN class=\"topicdescriptionkind\">Scope</SPAN>:<p>The EU contribution aims to facilitate the coordination and networking between charities themselves as well as with relevant stakeholders across Member States and Associated Countries. The EU contribution will not co-fund the trials.</p><p>Proposals should address all of the following:</p><ul level=\"0\"><li>Together, registered cancer charities and foundations across Europe, organise, fund and implement at least two transnational calls for proposals, resulting in grants to academic investigator-led third parties to conduct randomised multi-centre pragmatic clinical trials. The trials should deliver, affordable, accessible and evidence-based treatment or care interventions for implementation by healthcare systems at the level of local communities, European regions, Member States and Associated Countries.</li><li>Organise annual networking activities between charities, the successful academic investigators, citizen representatives and stakeholders across Member States and Associated Countries across Europe;</li><li>With respect to the pragmatic trials.</li><li>The chosen intervention(s) should be adapted to the particular needs of the target population and to the specificities of the provision of care at local, regional, or national level, duly reflecting the diversity across Member States and Associated Countries.</li><li>The chosen intervention(s) should take into account socio-economic and biological stratification. All data should be disaggregated by sex, gender, age and other relevant variables, such as by measures of socio-economic status.</li><li>The successful grants to third parties will address interventions for patients with cancers with a 5-year overall survival of less than 50% from time of diagnosis<sup><a target=_self href=#fn2 id=r2>[2]</a></sup> or rare cancers<sup><a target=_self href=#fn3 id=r3>[3]</a></sup>, at any stage of the disease, for any cancer subtype, in any age group or part of society.</li><li>Timely contact with regulatory authorities should be foreseen to inform the trial design and feasibility.</li> </ul><p>This topic requires the effective contribution of SSH disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise in the successful proposal, to produce meaningful and significant effects enhancing the societal impact of the related research activities.</p><p>The successful proposal is expected to build on the support of the Knowledge Centre on Cancer (KCC)<sup><a target=_self href=#fn4 id=r4>[4]</a></sup> to foster EU alignment and coordination.</p><p>The Commission will facilitate coordination. Therefore, successful proposals will be asked to join the 'Diagnostics and Treatment' cluster for the Mission on Cancer established in 2022<sup><a target=_self href=#fn5 id=r5>[5]</a></sup> and should include a budget for networking, attendance at meetings, and potential joint activities without the prerequisite to give details of these at this stage. Examples: organising joint workshops, establishing best practices, joint communication or citizen engagement activities with projects funded under other clusters and pillars of Horizon Europe, or other EU programmes, as appropriate. The details of joint activities will be defined during the grant agreement preparation phase and during the life of the project.</p>\n<p id=fn1><a  target=_self href=#r1>[1]</a>Under the Mission work programme a Europe-wide research and data platform, UNCAN.eu, will be established, utilising existing, relevant research infrastructures. Once operational, the platform should enable integration of innovative models and technologies with longitudinal patient data, data beyond research, or the health domain, samples and biomarkers for translation to patients.</p><p id=fn2><a  target=_self href=#r2>[2]</a>So called \u2018refractory cancers\u2019</p><p id=fn3><a  target=_self href=#r3>[3]</a>Defined as cancers with an incidence of less than 6 per 100,000 persons per year. See: <a href=\"https://www.rarecarenet.eu/rarecarenet/cancerlist\">https://www.rarecarenet.eu/rarecarenet/cancerlist</a>.</p><p id=fn4><a  target=_self href=#r4>[4]</a>Hosted by the European Commission's Joint Research Centre (JRC). Especially through the \u2019European Guidelines and Quality Assurance Schemes for Breast, Colorectal and Cervical Cancer Screening and Diagnosis\u2018, and the \u2019European Cancer Information System (ECIS)\u2019 and the \u2019European Cancer Inequalities Registry (ECIR), see <a href=\"https://knowledge4policy.ec.europa.eu/cancer_en\">https://knowledge4policy.ec.europa.eu/cancer_en</a></p><p id=fn5><a  target=_self href=#r5>[5]</a>In order to address the objectives of the Mission on Cancer, participants will collaborate in project clusters to leverage EU-funding, increase networking across sectors and disciplines, and establish a portfolio of Cancer Mission R&amp;I and policy actions.</p>", "conditions": "<h1><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: medium;\"><span style=\"font-family: Arial;\"><b><span style=\"line-height: 115%;\" lang=\"EN-US\">General conditions</span></b></span></span></span></h1>\r\n<p class=\"MsoNormal\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">1. Admissibility conditions: </span></b><span lang=\"EN-US\">described in </span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex A</span></span></a></span></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> </span><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">and </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:&#xA;Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex E</span></span></a></span></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of the Horizon Europe Work Programme General Annexes</span></span></span></p>\n<p style=\"margin-left: 40px;\"><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Proposal page limits and layout:</span></b><span lang=\"EN-US\"> described in Part B of the Application Form available in the Submission System</span></span></span></span></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">2. Eligible countries: </span></b><span lang=\"EN-US\">described in </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;&#xA;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex B</span></span></a></span></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> </span></span></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">of the Work Programme General Annexes</span></span></span></span><span style=\"mso-ansi-language:EN-US\" lang=\"EN-US\"><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-left: 40px;\"><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:&#xA;minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Horizon Europe Programme Guide</span></span></a></span></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">.</span></span></span></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b style=\"mso-bidi-font-weight:normal\"><span lang=\"EN-US\">3. Other eligibility conditions:</span></b><span lang=\"EN-US\"> described in </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:&#xA;Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex B</span></span></a></span></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"> <span lang=\"EN-US\">of the Work Programme General Annexes</span></span></span></span></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b>4. Financial and operational capacity and exclusion: </b>described in </span></span></span><span style=\"mso-bidi-font-weight:bold\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex C</span></span></a></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"> of the Work Programme General Annexes</span></span></span></p>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"FR-BE\">5.&nbsp;Evaluation and award:</span></b></span></span></span></p>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\">\r\n    <p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Award criteria, scoring and      thresholds</span></b><span lang=\"EN-US\"> are      described in </span></span></span></span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex      D</span></span></a></span><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> </span><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">of      the Work Programme General Annexes</span></span></span></span><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n    </li>\r\n</ul>\n<p>The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 3 (Implementation). The cumulative threshold will be 12.</p>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\">\r\n    <p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Submission and evaluation      processes</span></b><span lang=\"EN-US\"> are      described in </span></span></span></span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex      F</span></span></a></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of      the Work Programme General Annexes and the </span></span></span></span><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Online      Manual</span></span></a><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n    </li>\r\n</ul>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\">\r\n    <p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Indicative timeline for      evaluation and grant agreement: </span></b><span lang=\"EN-US\">described in </span></span></span></span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex      F</span></span></a></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of the Work Programme General Annexes</span></span></span></span><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n    </li>\r\n</ul>\n<p><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b style=\"mso-bidi-font-weight:normal\"><span lang=\"EN-US\">6. Legal and financial set-up of the grants: </span></b><span lang=\"EN-US\">described in </span></span></span></span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:&#xA;minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Annex G</span></span></a></span></span><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\"> of the Work Programme General Annexes</span></span></span></span></p>\r\n<p>&nbsp;</p>\n<h1><span style=\"font-size: medium;\"><span style=\"font-family: Arial;\"><b><span style=\"line-height: 115%;\" lang=\"EN-US\">Specific conditions</span></b></span></span><b><span style=\"font-size:12.0pt;mso-bidi-font-size:&#xA;11.0pt;line-height:115%;mso-ansi-language:EN-US\" lang=\"EN-US\"><o:p></o:p></span></b></h1>\r\n<p class=\"MsoNormal\"><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">7. Specific conditions: </span></b><span lang=\"EN-US\">described in the [specific topic of the Work Programme]</span></span></span></span></p>\r\n<p class=\"MsoNormal\">&nbsp;</p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-US\"><o:p></o:p></span></p>\n<h1><span style=\"font-size: medium;\"><b><span style=\"line-height: 115%;\" lang=\"EN-US\"><span style=\"font-family: Arial;\">Documents</span></span></b></span><b><span style=\"font-size:12.0pt;mso-bidi-font-size:&#xA;11.0pt;line-height:115%;mso-ansi-language:EN-US\" lang=\"EN-US\"><o:p></o:p></span></b></h1>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span style=\"color: rgb(0, 0, 0);\"><b><span lang=\"EN-US\">Call documents:</span></b></span></span></span><b><span lang=\"EN-US\"><o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">Standard application form</span></span><span style=\"color: rgb(128, 128, 128);\"><span lang=\"EN-US\"> &mdash;<i style=\"mso-bidi-font-style:normal\"> call-specific application form is available in the Submission System</i></span></span></span></span><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n<p><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/af_he-csa_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Standard application form (HE CSA)</span></span></a></p>\r\n<p><span style=\"font-size: small;\"><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">Standard evaluation form</span></span><span style=\"color: rgb(128, 128, 128);\"><span lang=\"EN-US\"> &mdash;<i style=\"mso-bidi-font-style:normal\"> will be used with the necessary adaptations</i></span></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/ef/ef_he-csa_en.pdf\"><span style=\"font-size: small;\"><span lang=\"EN-US\">Standard evaluation form (HE CSA)</span></span></a></p>\r\n<p><span style=\"font-size: small;\"><span style=\"color: rgb(0, 0, 0);\"><span lang=\"EN-US\">MGA</span></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/agr-contr/general-mga_horizon-euratom_en.pdf\" style=\"font-size: small;\"><span style=\"font-size: small;\">HE <span lang=\"EN-US\">General MGA v1.0</span></span></a></p>\r\n<p><span style=\"font-size: small;\"><span style=\"color: rgb(64, 64, 64);\" lang=\"EN-US\">Call-specific instructions</span></span></p>\r\n<p><span style=\"color: rgb(64, 64, 64);\" lang=\"EN-US\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/information-on-clinical-studies_he_en.docx\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Information on clinical studies (HE)</span></span></a><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/ls-funding-what-do-i-need-to-know_he_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><br />\r\n</span></span></a></span></p>\n<h2><span style=\"color: rgb(0, 0, 0);\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><b><span lang=\"EN-US\">Additional documents:</span></b></span></span></span><b><span lang=\"EN-US\"><o:p></o:p></span></b></h2>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-1-general-introduction_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 1. General Introduction</span></span></a></p>\r\n<p><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-12-missions_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 12. Missions</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2023-2024/wp-13-general-annexes_horizon-2023-2024_en.pdf\" target=\"_blank\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Main Work Programme 2023&ndash;2024 &ndash; 13. General Annexes</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">HE Programme Guide</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021R0695\" target=\"_blank\" style=\"font-family: Arial;\"><span style=\"font-size: small;\">HE Framework Programme and Rules for Participation Regulation 2021/695</span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-family: Arial;\"><span style=\"color: rgb(64, 64, 64);\" lang=\"EN-US\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021D0764\" target=\"_blank\"><span style=\"font-size: small;\">HE Specific Programme Decision 2021/764</span></a></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32018R1046&amp;qid=1535046024012\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">EU Financial Regulation</span></span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/rules-lev-lear-fca_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/aga_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">EU Grants AGA </span>&mdash; Annotated Model Grant Agreement</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\"><span lang=\"EN-US\">Funding &amp; Tenders Portal Online Manual</span></span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/ftp/tc_en.pdf\"><span style=\"font-size: small;\"><span style=\"font-family: Arial;\">Funding &amp; Tenders Portal Terms and Conditions</span></span></a></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/ftp/privacy-statement_en.pdf\" style=\"font-size: 11pt; font-family: Arial;\"><span style=\"font-size: small;\">Funding &amp; Tenders Portal Privacy Statement</span></a></p>", "supportInfo": "<p><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;&#10;font-weight:normal;mso-bidi-font-weight:bold\"><b><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\" target=\"_blank\">Online Manual</a>&nbsp;</b></span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">is your guide on the procedures from proposal submission to managing your grant.<o:p></o:p></span></p>\r\n<p><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\" target=\"_blank\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\">Horizon Europe Programme Guide</span></b></a><strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;</span></strong><strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif; font-weight: normal;\">contains the detailed guidance to the structure, budget and political priorities of Horizon Europe.</span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/faq;type=undefined;categories=;programme=H2020;actions=;keyword=\" target=\"_blank\">Funding &amp; Tenders Portal FAQ</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;&ndash; find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/research-and-innovation/contact/research-enquiry-service_en\" target=\"_blank\">Research Enquiry Service</a></span>&nbsp;</b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.</span></p>\r\n<p><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></p>\r\n<p><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/ncp\" target=\"_blank\">National Contact Points (NCPs)</a>&nbsp;</span></b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; get guidance, practical information and assistance on participation in Horizon Europe. There are also NCPs in many non-EU and non-associated countries (&lsquo;third-countries&rsquo;).<b><o:p></o:p></b></span></p>\r\n<p><a href=\"https://een.ec.europa.eu/\" target=\"_blank\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\">Enterprise Europe Network</span></b></a><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;&#10;color:#003366\">&nbsp;</span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/helpdesks/contact-form\" target=\"_blank\">IT Helpdesk</a></span></b>&nbsp;</span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash;&nbsp;contact the Funding &amp; Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://www.iprhelpdesk.eu/\" target=\"_blank\">European IPR Helpdesk</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;assists you on intellectual property issues.<br />\r\n<br />\r\n</span><b><a href=\"mailto:research@cencenelec.eu\" target=\"_blank\">CEN-CENELEC Research Helpdesk</a> and <a href=\"https://www.etsi.org/research/helpdesk\" target=\"_blank\">ETSI Research Helpdesk</a></b>&nbsp;<span style=\"font-family: Arial, sans-serif;\">&ndash;&nbsp;</span>the European Standards Organisations&nbsp;advise you how to tackle standardisation in your project proposal.&nbsp;&nbsp;</p>\r\n<p class=\"MsoNormal\" style=\"margin-left:36.0pt\"><o:p></o:p></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://euraxess.ec.europa.eu/sites/default/files/am509774cee_en_e4.pdf\" target=\"_blank\">The European Charter for Researchers and the Code of Conduct for their recruitment</a></span></b></span><span style=\"font-size:&#10;9.0pt;font-family:&quot;Arial&quot;,sans-serif;color:#003366\"> </span><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;color:#003366;font-weight:&#10;normal;mso-bidi-font-weight:bold\">&ndash; consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers.</span></strong><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></b></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/partner-search\" target=\"_blank\">Partner Search Services</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;help you find a partner organisation for your proposal.<o:p></o:p></span></p>\r\n<p>&nbsp;</p>", "sepTemplate": "<p>To access the Electronic Submission Service, please click on the submission-button next to the <strong>type of action</strong> and the <strong>type of model grant agreement</strong> that corresponds to your proposal. You will then be asked to confirm your choice, as it cannot be changed in the submission system. Upon confirmation, you will be linked to the correct entry point.</p>\r\n<p>To access existing draft proposals for this topic, please login to the Funding &amp; Tenders Portal and select the My Proposals page of the My Area section.</p>", "links": [{"callIdentifier": "HORIZON-MISS-2024-CANCER-01", "status": "Open", "criterionType": "SubFundingScheme", "criterionTypeDescription": "subfunding schemes", "criterionCode": "HORIZON-CSA", "criterionDescription": "HORIZON Coordination and Support Actions", "url": "https://ec.europa.eu/research/participants/submission/manage/screen/submission/create-draft/36441?topic=HORIZON-MISS-2024-CANCER-01-04", "startDate": "Apr 18, 2024 12:00:00 AM", "endDate": "Sep 18, 2024 5:00:00 PM", "mgaDescription": "HORIZON Action Grant Budget-Based", "mgaCode": "HORIZON-AG"}], "additionalDossiers": [], "infoPackDossiers": [], "callDetailsJSONItem": {"latestInfos": [{"approvalDate": "Apr 18, 2024 12:00:05 AM", "lastChangeDate": "Apr 18, 2024 12:00:05 AM", "content": "The submission session is now available for: HORIZON-MISS-2024-CANCER-01-01(HORIZON-RIA), HORIZON-MISS-2024-CANCER-01-04(HORIZON-CSA), HORIZON-MISS-2024-CANCER-01-02(HORIZON-CSA), HORIZON-MISS-2024-CANCER-01-03(HORIZON-IA), HORIZON-MISS-2024-CANCER-01-05(HORIZON-RIA), HORIZON-MISS-2024-CANCER-01-06(HORIZON-IA)"}], "hasForthcomingTopics": false, "hasOpenTopics": true, "allClosedTopics": false}}}